
Addex Therapeutics fell 63.1% from $8.30 to $3.06, behind the S&P 500's +10.6%. Its worst day was Nov 13 (−23.3%), and its low came Nov 9 at $2.74.
Nov 18, 2025 – Nov 18, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-1.50 was reported on $62,500.00 revenue.
+3.5% · S&P 500 +0.1%
Addex Therapeutics closed at its highest level of the year, 2.9% above where the year started.
Story events cover the past 12 months · Times ET
+9.2% · S&P 500 −0.4%
EPS of $-1.50 was reported on $20,020.00 revenue.
+4.3% · S&P 500 +1.0%
EPS of $-1.53 was reported on $10,214.00 revenue.
−4.8% · S&P 500 +0.1%
Addex Therapeutics shares fell 20.4%, while the S&P 500 fell 0.8%.
−20.4% · S&P 500 −0.8%
EPS of $-2.16 was reported on $12,650.00 revenue.
−19.2% · S&P 500 −0.7%
Addex Therapeutics closed at its lowest level of the year, 67.0% below where the year started.
−5.8% · S&P 500 +2.4%
Where it ended: a close of $3.06 on Nov 18, 2026. Up next: Q3 2026 earnings on Nov 23, 2026.
Nothing in the past 12 months.
All ADXN analyst actionsNothing in the past 12 months.
All ADXN dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ADXN and SPY from Benzinga historical bars. Not investment advice.